Combine searches by placing the search numbers in the top search box and pressing the search button. An example search might look like (#1 or #2) and (#3 or #4)
Latest & greatest articles for colorectal cancer
The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on colorectal cancer or other clinical topics then use Trip today.
This page lists the very latest high quality evidence on colorectal cancer and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.
What is Trip?
Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.
Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.
As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.
For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via email@example.com
fruits and vegetables, fiber, and calcium). Awareness Given the data that colorectalcancer is increasing in younger individuals we must be more vigilant for signs and symptoms that could indicate a problem. I want to know if you develop blood in your stools, anemia, abdominal pain, or changes in bowel habits. However, it is also important to realize that early coloncancers and precancerous polyps do not commonly cause symptoms. 5 References American Academy of Family Physicians Statement: https (...) -decision making to discuss the risks and benefits • It is strongly recommended that all average risk patients 50 years and older should be screened for coloncancer • Extra vigilance for symptoms and risk factors of coloncancer (including family history in people aged 45-49) is advised given increasing colorectalcancer rates in this group. Definition of Average Risk This guidance applies to individuals at average risk for colorectalcancer. Patients not considered average risk include those
Breast/Ovarian Hereditary Cancer Syndromes Cancers of Unknown Primary Site Cancers of Unknown Primary Site Endocrine and Neuroendocrine Cancers Neuroendocrine Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid CancerGastrointestinalCancers Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancer • Cancer of the pancreas • Metastatic colorectalcancer • Anal cancer • Early coloncancer • Familial risk colorectalcancer • Hepatocellular (...) Algorithm eUpdate - Early ColonCancer Algorithm Published: 23 September 2019. Authors: ESMO Guidelines Committee Clinical Practice Guidelines This eUpdate refers to the . R. Labianca, B. Nordlinger, G. D. Beretta, S. Mosconi, M. Mandalà, A. Cervantes, D. Arnold. Ann Oncol 2013; 24 (Suppl 6): vi64–vi72. Section Management of local/locoregional disease Algorithm Text update This eUpdate provides a new Figure 1. Therapeutic algorithm for treatment of localised colorectalcancer ESMO is a Swiss-registered
Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness | CADTH.ca Find the information you need Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness Occult Blood Detection Testing for Non-ColorectalCancer Related Medical Conditions: Clinical Effectiveness Last updated: April 15 (...) , 2019 Project Number: RA1026-000 Product Line: Research Type: Devices and Systems Report Type: Reference List Result type: Report Question What is the clinical effectiveness of the fecal immunochemical test in detecting medical conditions other than colorectalcancer where occult blood detection is needed? What is the clinical effectiveness of the guaiac fecal blood occult test in detecting medical conditions other than colorectalcancer where occult blood detection is needed? Key Message
Type Gastrointestinal / Lung Indication Metastatic ColorectalCancer / Non-Small Cell Lung Cancer Biosimilar Funding Request For first-line treatment of patients with metastatic carcinoma of the colon or rectum, in combination with fluoropyrimidine based chemotherapy / For treatment of patients with unresectable advanced, metastatic or recurrent non-squamous non-small cell lung cancer, in combination with carboplatin/paclitaxel chemotherapy regimen Review Status Final Biosimilar Dossier Issued Pre (...) Mvasi for Metastatic ColorectalCancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic ColorectalCancer / Non-Small Cell Lung Cancer Biosimilar – Details | CADTH.ca Find the information you need Mvasi for Metastatic ColorectalCancer / Non-Small Cell Lung Cancer Biosimilar – Details Mvasi for Metastatic ColorectalCancer / Non-Small Cell Lung Cancer Biosimilar – Details Project Number pCODR 10158 Brand Name Mvasi Generic Name Bevacizumab Strength 100 mg and 400 mg Tumour
Hereditary Cancer Syndromes Cancers of Unknown Primary Site Cancers of Unknown Primary Site Endocrine and Neuroendocrine Cancers Neuroendocrine Bronchial and Thymic Tumours • Neuroendocrine Gastroenteropancreatic Tumours • Adrenal Cancer • Thyroid CancerGastrointestinalCancers Rectal Cancer • Biliary cancer • Gastric cancer • Oesophageal cancer • Cancer of the pancreas • Metastatic colorectalcancer • Anal cancer • Early coloncancer • Familial risk colorectalcancer • Hepatocellular carcinoma (...) Updated treatment recommendations for Early ColonCancer Early ColonCancer Treatment Recommendations | ESMO Welcome to the EUROPEAN SOCIETY FOR MEDICAL ONCOLOGY , the leading European professional organisation for medical oncology. Search Careers at ESMO ESMO Oncology Journals Our journals offer ESMO members and the oncology community a globally visible platform to publish scientific studies, and a highly credible source of educational updates. Connect with ESMO Discover ESMO's new social
words 3 | P a g e Abstract These consensus guidelines were jointly commissioned by the British Society of Gastroenterology, the Association of Coloproctology of Great Britain and Ireland and Public Health England. They provide an evidence-based framework for the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 and over. They are the first guidelines that take into account the introduction of national bowelcancer screening. For the first time, they also (...) Health England; PHE) and supported by NHS England (NHSE). These guidelines consider the use of surveillance colonoscopy and non-colonoscopic colorectal imaging in people aged 18 and over and are an update of current BSG/ACPGBI post-polypectomy and post-CRC resection colorectal surveillance guidelines (first published in 2002, last revised in 2010 [containing evidence up to 2006]) (14, 15); they are the first guidelines that take into account the introduction of national bowelcancer screening
; Strength of recommendation: strong) o We suggest that when abdominal-perineal excision can be avoided, a standard low anterior resection is a reasonable option to treat rectal cancers in LS patients, even though the residual colon is at high-risk of metachronous neoplasia. (GRADE of evidence: low; Strength of recommendation: weak) o We recommend that gastric, small bowel, or pancreatic surveillance in LS patients is only performed in the context of a clinical trial. (GRADE of evidence: low; Strength (...) neoplasia. ATZ: anal transitional zone. BSG: British Society of Gastroenterology. BSGM: British society of genetic medicine. CHRPE: congenital hypertrophy retinal pigmentation epithelium. CI: confidence intervals. COX-2: Cyclooxygenase-2 . CRC: colorectalcancer. CSSC: Clinical Services and Standards Committee. EHTG: European Hereditary Tumour Group. EOCRC: Early onset CRC. ESGE: European Society of Gastrointestinal Endoscopy. FAP: Familial adenomatous polyposis. FDR: First-degree relative. FH: family
Strength 15 mg & 20 mg Tumour Type Gastrointestinal Indication Metastatic ColorectalCancer Funding Request Treatment of adult patients with mCRC who have been previously treated with, or are not candidates for, available therapies including fluoropyrimidine-, oxaliplatin- and irinotecan-based chemotherapies, anti-VEGF biological agents, and, if RAS wild-type, anti-EGFR agents Review Status Notification to Implement Issued Pre Noc Submission No NOC Date January 25, 2018 Manufacturer Taiho Pharma Canada (...) Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details | CADTH.ca Find the information you need Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details Trifluridine and Tipiracil (Lonsurf) for Metastatic ColorectalCancer Resubmission – Details Project Number pCODR 10173 Brand Name Lonsurf Generic Name Trifluridine and Tipiracil
Whole body MRI is effective for identifying metastatic disease in colorectalcancer patients. The studyTaylor S, Mallett S, Beare S et al. Diagnostic accuracy of whole-body MRI versus standard imaging pathways for metastatic disease in newly diagnosed colorectalcancer: the prospective Streamline C trial. Lancet Gastroenterol Hepatol 2019;4:529-37.This project was funded by the NIHR Health Technology Assessment Programme (project number 10/68/01).To read the full NIHR Signal, go to https (...) ://discover.dc.nihr.ac.uk/content/signal-000797/identifying-metastatic-disease-in-colorectal-cancer-with-whole-body-mri.Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
данных PubMed по различным комбинациям слов: coloncancer, colorectalcancer, rectal cancer, CRC, mCRC, или colon neoplasms [MeSH terms], rectal neoplasms [MeSH terms], colorectal neoplasms [MeSH terms] и regorafenib. Проведен поиск всех статей с публикацией по март 2019 г. Компьютерный поиск был дополнен изучением списка литературы обзорных статей и оригинальных работ, а также тезисов, представленных на конференциях ASCO (American Society of Clinical Oncology) и ESMO (European Society for Medical (...) , phase 3 trial. Lancet 2013; 381: 303-12. Van Cutsem E, Martinelli E, Cascinu S et al. Regorafenib for Patients with Metastatic ColorectalCancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study. Oncologist 2019; 24 (2): 185-92. Schulz H, Janssen J, Strauss U.P et al. Clinical efficacy and safety of regorafenib (REG) in the treatment of metastatic colorectalcancer (mCRC) in daily practice in Germany: Final results of the prospective
Follow-up strategies for patients treated for non-metastatic colorectalcancer. This is the fourth update of a Cochrane Review first published in 2002 and last updated in 2016.It is common clinical practice to follow patients with colorectalcancer for several years following their curative surgery or adjuvant therapy, or both. Despite this widespread practice, there is considerable controversy about how often patients should be seen, what tests should be performed, and whether these varying (...) strategies have any significant impact on patient outcomes.To assess the effect of follow-up programmes (follow-up versus no follow-up, follow-up strategies of varying intensity, and follow-up in different healthcare settings) on overall survival for patients with colorectalcancer treated with curative intent. Secondary objectives are to assess relapse-free survival, salvage surgery, interval recurrences, quality of life, and the harms and costs of surveillance and investigations.For this update, on 5
Inflammatory Bowel Disease and the Risk of Prostate Cancer: A Meta-analysis of Cohort Studies Inflammatory Bowel Disease and the Risk of Prostate Cancer: A Meta-analysis of Cohort Studies | Research Square Browse Tools & Services Your Cart This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint on this server should not be interpreted (...) as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article Inflammatory Bowel Disease and the Risk of Prostate Cancer: A Meta-analysis of Cohort Studies Wen-Qing Lian, Hong-Xing Huang, Fa-Jiang Li, Liang-Hua Chen Wen-Qing Lian Zhongshan Affiliated Hospital of Sun Yat-sen University Corresponding Author Hong-Xing Huang Zhongshan Affiliated Hospital of Sun Yat-sen University Fa-Jiang Li Zhongshan Affiliated Hospital of Sun Yat
Multicentre randomized clinical trial of colonic J pouch or straight stapled colorectal reconstruction after low anterior resection for rectal cancerColonic J pouch reconstruction has been found to be associated with a lower incidence of anastomotic leakage than straight anastomosis. However, studies on this topic are underpowered and retrospective. This randomized trial evaluated whether the incidence of anastomotic leakage was reduced after colonic J pouch reconstruction compared (...) with straight colorectal anastomosis following anterior resection for rectal cancer.This multicentre RCT included patients with rectal carcinoma who underwent low anterior resection followed by colorectal anastomosis. Patients were assigned randomly to receive a colonic J pouch or straight colorectal anastomosis. The main outcome measure was the occurrence of major anastomotic leakage. The incidence of global (major plus minor) anastomotic leakage and general complications were secondary outcomes. Risk
polyposis and colorectalcancer. Nat Genet 2015; 47: 668-671. 54. Moreira L, Pellise M, Carballal S et al. High prevalence of serrated polyposis syndrome in FIT-based colorectalcancer screening programmes. Gut 2013; 62: 476-477. 55. Carballal S, Rodriguez-Alcalde D, Moreira L et al. Colorectalcancer risk factors in patients with serrated polyposis syndrome: a large multicentre study. Gut 2016; 65: 1829- 1837. 56. Bosman F, Carneiro F, Hruban R, Theise N. WHO classification of tumours of the digestive (...) concerns associated to each genetic susceptibility. These guidelines aim to summarise the evidence-based data on hereditary colorectalcancer (CRC), gastric cancer (GC) and pancreatic cancer (PC) and provide useful clinical recommendations for identification and management of patients with hereditary gastrointestinalcancers. HEREDITARY NON-POLYPOSIS COLORECTALCANCER SYNDROME (LYNCH SYNDROME) Prevalence and penetrance LS accounts for 1%–3% of all CRC diagnoses . It is caused by germline mutations
Perioperative FOLFOX 4 Versus FOLFOX 4 Plus Cetuximab Versus Immediate Surgery for High-Risk Stage II and III ColonCancers: A Phase II Multicenter Randomized Controlled Trial (PRODIGE 22) Perioperative chemotherapy has proven valuable in several tumors, but not in coloncancer (CC).The aim of this study was to evaluate the efficacy and safety of perioperative chemotherapy in patients with locally advanced nonmetastatic CC.This is a French multicenter randomized phase II trial in patients
Tissue micro-RNAs associated with colorectalcancer prognosis: a systematic review Tissue micro-RNAs associated with colorectalcancer prognosis: a systematic review | bioRxiv Search for this keyword New Results Tissue micro-RNAs associated with colorectalcancer prognosis: a systematic review Igor Lopes dos Santos , Karlla Greick Batista Dias Penna , Megmar Aparecida dos Santos Carneiro , Larisse Silva Dalla Libera , Jéssica Enocencio Porto Ramos , Vera Aparecida Saddi doi: https://doi.org (...) in the review. The studies investigated the expression of 102 different miRs associated with prognostic aspects in colorectalcancer patients. The most frequent oncogenic miRs investigated were miR-21, miR-181a, miR-182, miR-183, miR-210 and miR-224 and the hyperexpression of these miRs was associated with distant metastasis, lymph node metastasis and worse survival in patients with CRC. The most frequent tumor suppressor miRs were miR-126, miR-199b and miR-22 and the hypoexpression of these miRs
A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectalcancer A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectalcancer | Research Square Browse Tools & Services Your Cart See the published version of this article at . This is a preprint, a preliminary version of a manuscript that has not completed peer review at a journal. Research Square does not conduct peer review prior to posting preprints. The posting of a preprint (...) on this server should not be interpreted as an endorsement of its validity or suitability for dissemination as established information or for guiding clinical practice. Research article A pair-wise meta-analysis highlights circular RNAs as potential biomarkers for colorectalcancer Chen Li, Xinli He, Lele Zhang, Lanying Li, Wenzhao Zhao Chen Li The First Affiliated Hospital, and College of Clinical Medicine of Henan University of Science and Technology Xinli He The First Affiliated Hospital, and College
Atezolizumab with or without cobimetinib versus regorafenib in previously treated metastatic colorectalcancer (IMblaze370): a multicentre, open-label, phase 3, randomised, controlled trial Microsatellite-stable metastatic colorectalcancer is typically unresponsive to immunotherapy. This phase 3 study was designed to assess atezolizumab plus cobimetinib in metastatic colorectalcancer. Here, we report the comparison of atezolizumab plus cobimetinib or atezolizumab monotherapy versus (...) regorafenib in the third-line setting.IMblaze 370 is a multicentre, open-label, phase 3, randomised, controlled trial, done at 73 academic medical centres and community oncology practices in 11 countries. Patients aged at least 18 years with unresectable locally advanced or metastatic colorectalcancer, baseline Eastern Cooperative Oncology Group performance status of 0-1, and disease progression on or intolerance to at least two previous systemic chemotherapy regimens were enrolled. We used permuted